Whole Genome and Exome Sequencing Markets. by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are over 800 locations that have high throughput devices?

Our facts and support = Your success.

A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out five years. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

B.Sc. (Chemistry) University of BC
M.B.A. (Finance and Policy) University of BC
Market Research Seminar - Burke Institute
Finance for Senior Executives - Harvard Business School

1 Market Guides

1.1 Whole Genome Sequencing Market - Strategic Situation Analysis
1.2 Guide for Executives, Marketing, Sales and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

2.1 Whole Genome Sequencing Definition In This Report
- 2.1.1 Whole and Exome Sequencing
- 2.1.2 Research and Clinical
- 2.1.3 Clinical Tumor
- 2.1.4 Clinical Pathogen
- 2.1.5 Agri/Other
- 2.1.6 Direct to Consumer
2.2 The Genomics Revolution
2.3 Market Definition
- 2.3.1 Revenue Market Size
2.4 Methodology
- 2.4.1 Methodology
- 2.4.2 Sources
- 2.4.3 Authors
2.5 Perspective: Healthcare and the IVD Industry
- 2.5.1 Global Healthcare Spending
- 2.5.2 Spending on Diagnostics
- 2.5.3 Important Role of Insurance for Diagnostics
2.6 Sizing the Genome - Not What You Think
- 2.6.1 Cost, Price and Genome Size, Pricing Practice
2.7 GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE
- Location & Contacts

3 Market Overview

3.1 Market Participants Play Different Roles
- 3.1.1 Instrument Manufacturer
- 3.1.2 Independent lab specialized/esoteric
- 3.1.3 Independent lab national/regional
- 3.1.4 Independent lab analytical
- 3.1.5 Public National/regional lab
- 3.1.6 Hospital lab
- 3.1.7 Physician lab
- 3.1.8 DTC Lab
- 3.1.9 Sequencing Labs
- 3.1.10 Audit body
3.2 Whole Genome Sequencing -Markets, Examples and Discussion
- 3.2.1 Direct to Consumer - Two Approaches
  - 3.2.1.1 The New Age of Medical Information
  - 3.2.1.2 Dangers in DTC-WGS - Health Costs and Regulation
  - 3.2.1.3 Newborn and Prenatal - A Brave New World
  - 3.2.1.4 DTC - How Many Segments?
- 3.2.2 Research Markets
  - 3.2.2.1 Research Funding and Capital Expense
  - 3.2.2.2 WGS Datasets Preferred
  - 3.2.2.3 Existing research repurposed
  - 3.2.2.4 Organism Wide Market
  - 3.2.2.5 Service Suppliers Respond
- 3.2.3 Clinical - Understanding Germline and Somatic
  - 3.2.3.1 Somatic - Chasing Mutations and Pharmacogenomics
- 3.2.4 Pathogen Testing
  - 3.2.4.1 The Hepatitis C Story
  - 3.2.4.2 Will the Microbiology Department Disappear?
- 3.2.5 AgriBio - Big Business
  - 3.2.5.1 GMO is Here to Stay
  - 3.2.5.2 WGS Benefits and Risks
  - 3.2.5.3 The New Agriculture
3.3 Industry Structure
- 3.3.1 Hospital's Testing Share
- 3.3.2 Economies of Scale
- 3.3.3 Instrument Manufacturer Role
- 3.3.4 Healthcare Industry Impacts - Still Struggling
  - 3.3.4.1 Can the Healthcare Industry Adapt?
  - 3.3.4.2 Genetic Counselling as an Industry
  - 3.3.4.3 WGES Adoption and Cannibalization
  - 3.3.4.4 The Meaning of Grail

4 Market Trends

4.1 Factors Driving Growth
- 4.1.1 Diagnostic Factors
- 4.1.2 Interpreting the Code Otherwise
- 4.1.3 Changes in Agriculture
- 4.1.4 Fertility Technology Comes of Age
- 4.1.5 Pathogen Challenges
4.2 Factors Limiting Growth
- 4.2.1 Increased Competition Lowers Price
- 4.2.2 Lower Costs
- 4.2.3 Healthcare Cost Concerns Curtail Growth
- 4.2.4 Wellness has a downside
- 4.2.5 GMO Opposition Movement
4.3 Sequencing Instrumentation
- 4.3.1 Instrumentation Tenacity
- 4.3.2 Declining Cost Changes Industry Structure
- 4.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
- 4.3.4 Illumina
- 4.3.5 ION
- 4.3.6 Pacific Biosystems
- 4.3.7 Roche 454
- 4.3.8 SOLiD
- 4.3.9 Oxford Nanopore
  - 4.3.9.1 What is Oxford Nanopore Sequencing?
  - 4.3.9.2 What can Oxford Nanopore Sequencingt be used for?
  - 4.3.9.3 Oxford Nanopore Products
- 4.3.10 Long Reads - Further Segmentation
- 4.3.11 Linked Reads
- 4.3.12 Targeted Sequencing Adopts CRISPR
- 4.3.13 New Sequencing Technologies
  - 4.3.13.1 RNAP sequencing
  - 4.3.13.2 In vitro virus high-throughput sequencing
  - 4.3.13.3 Tunnelling currents DNA sequencing
  - 4.3.13.4 Sequencing by hybridization
  - 4.3.13.5 Sequencing with mass spectrometry
  - 4.3.13.6 Microfluidic Sanger sequencing
  - 4.3.13.7 Microscopy-based techniques

5 WGES Recent Developments

5.1 Recent Developments - Importance and How to Use This Section
- 5.1.1 Importance of These Developments
- 5.1.2 How to Use This Section
5.2 Myriad Genetics to Study MRD Testing
5.3 Adela Developing Epigenetic Multi-Cancer Detection
5.4 Epic Sciences Expanding Infrastructure for Liquid Biopsy Test
5.5 Bionano Laboratories Announces New Prenatal Whole Genome Tests
5.6 Myriad Genetics Plans Product Launches
5.7 Genomics England, Aims to Sequence 100K Newborns
5.8 Juno Diagnostics NIPT With At-Home Sample Collection
5.9 Cardio Diagnostics Launches Genetic Cardio Risk Test
5.10 Universal Genetic Testing in Breast Cancer Further Supported
5.11 Aniling Gets CE-IVD Marks for Cancer Sequencing Tests
5.12 MyOme Lands Investment for WGS
5.13 GenomSys Gains CE Mark for New Genomic Analysis Software
5.14 WGS Finds Lung Cancers Fall Into Molecular Subtypes
5.15 Testing Distinguishes Benign Tumors From Precancerous Condition
5.16 Plan to Sequence All Newborns in UK
5.17 Clear Labs Raises $60M for Nanopore Sequencing
5.18 Variantyx Expands Into Prenatal, Cancer Testing
5.19 Whole-Genome Sequencing Aids Diagnosis in Stockholm
5.20 Variantyx Raises $20M
5.21 Nonacus WGS Service for SARS-CoV-2 Laboratories
5.22 Center to Report Risk Scores in Clinical WGS
5.23 Stanford Launches WGS for Cardiovascular Testing
5.24 Illumina and NY Healthcare Partner on Clinical WGS
5.25 Increased Adoption of WGS Needs Acceptance by Payors, Providers
5.26 Veritas Intercontinental Completes €5M Series B Financing Round
5.27 M2GEN and Discovery Life Sciences in Bioinformatics Agreement
5.28 Genomics England Adopts Quantum ActiveScale Object Storage
5.29 GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx
5.30 NHS Wales Introduces WGS for Critically Ill Newborns
5.31 Illumina Achieves EAU for NGS-Based SARS-CoV-2 Test
5.32 C2i Genomics to Launch Trials for MRD Detection Tech
5.33 Roche Acquires Sequencing Company Stratos Genomics
5.34 UK COVID-19 Sequencing Consortium Launches
5.35 Invitae Acquires Three Companies: YouScript, Genelex, Diploid
5.36 Experience From Centralized Genomic Medicine Lab
5.37 MGI to Enable $100 Human Genome
5.38 Nebula Genomics offers $299 WGS
5.39 Team to Study Campylobacter Omics
5.40 Veritas Genetics Restarts US Business
5.41 NEOGEN, Gencove partner to advance animal genomics

6 Profiles of Key Companies

6.1 10x Genomics, Inc.
6.2 1928 Diagnostics
6.3 23andME Inc.
6.4 Abbott Laboratories
6.5 AccuraGen Inc.
6.6 Adaptive Biotechnologies
6.7 Admera Health, LLC
6.8 Agilent/Dako
6.9 Akonni Biosystems
6.10 Amoy Diagnostics Co., Ltd.
6.11 Ancestry.com LLC
6.12 Anchor Dx
6.13 ARUP Laboratories
6.14 BaseClear
6.15 Baylor Miraca Genetics Laboratories
6.16 Beckman Coulter Diagnostics
6.17 Becton, Dickinson and Company
6.18 BGI Genomics Co. Ltd
6.19 Bioarray Genetics
6.20 Biocept, Inc.
6.21 Biodesix Inc.
6.22 BioFluidica
6.23 BioGenex
6.24 Biolidics Ltd
6.25 bioMérieux Diagnostics
6.26 Bioneer Corporation
6.27 Bio-Rad Laboratories, Inc
6.28 Bio-Techne
6.29 C2i Genomics
6.30 Caris Molecular Diagnostics
6.31 CellMax Life
6.32 Centogene
6.33 Circulogene
6.34 Clear Labs
6.35 Clinical Genomics
6.36 Complete Genomics, Inc. - A BGI Company
6.37 CosmosID
6.38 Dante Labs
6.39 Datar Cancer Genetics Limited
6.40 Day Zero Diagnostics.
6.41 Diasorin S.p.A.
6.42 Element Biosciences
6.43 Element Biosciences
6.44 Epic Sciences
6.45 Epigenomics AG
6.46 Eurofins Scientific
6.47 Excellerate Bioscience
6.48 Fabric Genomics
6.49 Freenome
6.50 FUJIFILM Wako Diagnostics
6.51 Fulgent Genetics
6.52 GE Global Research
6.53 Gencove
6.54 Genedrive
6.55 GeneFirst Ltd.
6.56 Genetron Holdings
6.57 Genewiz
6.58 Genomics England
6.59 Genomics Personalized Health (GPH)
6.60 GenomOncology
6.61 Genzyme Corporation
6.62 Grifols
6.63 Guardant Health
6.64 Guardiome
6.65 HeiScreen
6.66 Helix
6.67 Helix OpCo
6.68 Helomics
6.69 Hologic
6.70 HTG Molecular Diagnostics
6.71 Human Longevity, Inc.
6.72 iCellate
6.73 Illumina
6.74 Incell Dx
6.75 Inivata
6.76 Invitae Corporation
6.77 Invivoscribe
6.78 Karius
6.79 Lunglife AI Inc
6.80 Macrogen
6.81 MDNA Life SCIENCES, Inc.
6.82 MDx Health
6.83 Medgenome
6.84 Meridian Bioscience
6.85 Mesa Biotech (Thermo Fisher)
6.86 Mesa Laboratories, Inc.
6.87 miR Scientific
6.88 MNG Labs
6.89 NantHealth, Inc.
6.90 Natera
6.91 Nebula Genomics
6.92 NeoGenomics
6.93 New England Biolabs, Inc.
6.94 Novogene Bioinformatics Technology Co., Ltd.
6.95 Omega Bioservices
6.96 Oncocyte
6.97 OncoDNA
6.98 OpGen
6.99 ORIG3N, Inc.
6.100 Origene Technologies
6.101 Oxford Nanopore Technologies
6.102 Pacific Biosciences
6.103 Panagene
6.104 Pathogenomix
6.105 PathoQuest S.A.
6.106 Personal Genome Diagnostics
6.107 Personalis
6.108 Precipio
6.109 PrecisionMed
6.110 Promega
6.111 Protagen Diagnostics
6.112 Qiagen
6.113 QuantuMDx
6.114 Regeneron Pharmaceuticals
6.115 Revvity
6.116 Roche Molecular Diagnostics
6.117 Roswell Biotechnologies
6.118 Seegene
6.119 Sequencing.com
6.120 Siemens Healthineers
6.121 simfo GmbH
6.122 Singlera Genomics Inc.
6.123 Singular Genomics
6.124 SkylineDx
6.125 Standard BioTools
6.126 Sure Genomics, Inc.
6.127 Sysmex
6.128 Sysmex Inostics
6.129 Tempus Labs, Inc.
6.130 Thermo Fisher Scientific Inc.
6.131 Ultima Genomics
6.132 Ultima Genomics
6.133 Variantyx
6.134 Volition
6.135 Vyant Bio
6.136 Zymo Research Corp

7 The Global Market for Whole Genome Sequencing

7.1 Global Market Overview by Country
- 7.1.1 Table - Global Market by Country
- 7.1.2 Chart - Global Market by Country
7.2 Global Market by Application - Overview
- 7.2.1 Table - Global Market by Application
- 7.2.2 Chart - Global Market by Application - Base/Final Year Comparison
- 7.2.3 Chart - Global Market by Application - Base Year
- 7.2.4 Chart - Global Market by Application - Final Year
- 7.2.5 Chart - Global Market by Application - Share by Year
- 7.2.6 Chart - Global Market by Application - Segment Growth
7.3 Global Market by Organism - Overview
- 7.3.1 Table - Global Market by Organism
- 7.3.2 Chart - Global Market by Organism - Base/Final Year Comparison
- 7.3.3 Chart - Global Market by Organism - Base Year
- 7.3.4 Chart - Global Market by Organism - Final Year
- 7.3.5 Chart - Global Market by Organism - Share by Year
- 7.3.6 Chart - Global Market by Organism - Segment Growth
7.4 Global Market by Product - Overview
- 7.4.1 Table - Global Market by Product
- 7.4.2 Chart - Global Market by Product - Base/Final Year Comparison
- 7.4.3 Chart - Global Market by Product - Base Year
- 7.4.4 Chart - Global Market by Product - Final Year
- 7.4.5 Chart - Global Market by Product - Share by Year
- 7.4.6 Chart - Global Market by Product - Segment Growth

8 Global Whole Genome Sequencing Markets - by Application

8.1 Research
- 8.1.1 Table Research - by Country
- 8.1.2 Chart - Research Growth
8.2 Clinical Human
- 8.2.1 Table Clinical Human - by Country
- 8.2.2 Chart - Clinical Human Growth
8.3 Clinical Tumor
- 8.3.1 Table Clinical Tumor - by Country
- 8.3.2 Chart - Clinical Tumor Growth
8.4 Clinical Pathogen
- 8.4.1 Table Clinical Pathogen - by Country
- 8.4.2 Chart - Clinical Pathogen Growth
8.5 Direct to Consumer
- 8.5.1 Table Direct to Consumer - by Country
- 8.5.2 Chart - Direct to Consumer Growth
8.6 Agriculture/Other
- 8.6.1 Table Agriculture/Other - by Country
- 8.6.2 Chart - Agriculture/Other Growth

9 Global Whole Genome Sequencing Markets - by Organism

9.1 Human
- 9.1.1 Table Human - by Country
- 9.1.2 Chart - Human Growth
9.2 Pathogen
- 9.2.1 Table Pathogen - by Country
- 9.2.2 Chart - Pathogen Growth
9.3 Other Organism
- 9.3.1 Table Other Organism - by Country
- 9.3.2 Chart - Other Organism Growth

10 Global Whole Genome Sequencing Markets - by Product

10.1 Instruments
- 10.1.1 Table Instruments - by Country
- 10.1.2 Chart - Instruments Growth
10.2 Reagents
- 10.2.1 Table Reagents - by Country
- 10.2.2 Chart - Reagent Growth
10.3 Analysis
- 10.3.1 Table Analysis - by Country
- 10.3.2 Chart - Analysis Growth
10.4 Software & Other
- 10.4.1 Table Software & Other - by Country
- 10.4.2 Chart - Software & Other Growth

11 Vision of the Future of Whole Genome Sequencing

12 Appendices

12.1 United States Medicare System: Laboratory Fees Schedule
12.2 The Most Used IVD Assays
12.3 The Highest Grossing Assays
12.4 The Whole Genome Sequence of SARS-CoV-2

Table of Tables

Table 1 The Base Pairs
Table 2 Most Common Traditional Genetic Disorders
Table 3 List of GLOBAL SEQUENCING LOCATIONS
Table 4 Market Players by Type
Table 5 The Different Markets for Whole Genome Sequencing
Table 6 DTC Sub Segments
Table 7 Roles of WGS in AgriBio
Table 8 The Factors Driving Growth
Table 9 Factors Limiting Growth
Table 10 - Listing of Current NGS Instrument Specifications
Table 11 Six New Sequencing Technologies
Table 12 - Global Market by Region
Table 13 Global Market by Application
Table 14 Global Market by Organism
Table 15 Global Market by Product
Table 16 Research by Country
Table 17 Clinical Human by Country
Table 18 Clinical Tumor by Country
Table 19 Clinical Pathogen by Country
Table 20 Direct to Consumer by Country
Table 21 Agriculture/Other by Country
Table 22 Human by Country
Table 23 Pathogen by Country
Table 24 Other Organism by Country
Table 25 Instruments by Country
Table 26 Reagents by Country
Table 27 Analysis by Country
Table 28 Software & Other by Country
Table 29 Clinical Lab Fee Schedule
Table 30 The Most Common Assays
Table 31 Largest Revenue Assays

Table of Figures

Figure 1 Global Healthcare Spending
Figure 2 The Lab Test Pie
Figure 3 Size of Genome for Various Species
Figure 4 - Cost To Sequence a Human Genome
Figure 5 Base Year Country Market Share Chart
Figure 6 Global Market by Application - Base vs. Final Year
Figure 7 Global Market by Application Base Year
Figure 8 Global Market by Application Final Year
Figure 9 Application Type Share by Year
Figure 10 by Application Segment Growth
Figure 11 by Organism - Base vs. Final Year
Figure 12 by Organism Market Base Year
Figure 13 by Organism Market Final Year
Figure 14 by Organism Share by Year
Figure 15 by Organism Segment Growth
Figure 16 by Product - Base vs. Final Year
Figure 17 by Product Market Base Year
Figure 18 by Product Market Final Year
Figure 19 by Product Share by Year
Figure 20 by Product Segment Growth
Figure 21 Research Growth
Figure 22 Clinical Human Growth
Figure 23 Clinical Tumor Growth
Figure 24 Clinical Pathogen Growth
Figure 25 Direct to Consumer Growth
Figure 26 Agriculture/Other Growth
Figure 27 Human Growth
Figure 28 Pathogen Growth
Figure 29 Other Organism Growth
Figure 30 Instruments Growth
Figure 31 Reagent Growth
Figure 32 Analysis Growth
Figure 33 Software & Other Growth